VOLUME 3 (2012)
View Archive »
About The Cover
PRL-3 chimeric mAb recognizes EGFP-PRL-3 overexpressed in DLD-1 human colorectal cancer cells by indirect immunofluorescence. Shown is the composite image of EGFP-PRL-3 in fixed DLD-1 cells (green) and PRL-3 chimeric antibody together with an image of anti-human IgG Texas-Red (red) to reveal the binding to PRL-3 protein. See Guo et al.
|
|
Table of Contents
|
| cMYC and SIRT1 locked in a vicious cycle |
|
https://doi.org/10.18632/oncotarget.440
|
| 112-113 |
|
| Modulating Mesothelin Shedding to Improve Therapy |
|
https://doi.org/10.18632/oncotarget.445
|
| 114-115 |
|
| Bryostatin analog: improving on Nature’s design |
|
https://doi.org/10.18632/oncotarget.460
|
| 116-117 |
Reviews
|
| Targeting Mnks for Cancer Therapy |
|
https://doi.org/10.18632/oncotarget.453
|
| 118-131 |
Brief Reports
|
| Gainoffunction p53 mutants have widespread genomic locations partially overlapping with p63 |
|
https://doi.org/10.18632/oncotarget.447
|
| 132-143 |
Research Papers
|
| Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes |
|
https://doi.org/10.18632/oncotarget.420
|
| 144-157 |
|
| Engineering the First Chimeric Antibody in Targeting Intracellular PRL3 Oncoprotein for Cancer Therapy in Mice |
|
https://doi.org/10.18632/oncotarget.442
|
| 158-171 |
|
| Single Enantiomer of YK4279 Demonstrates Specificity in Targeting the Oncogene EWSFLI1 |
|
https://doi.org/10.18632/oncotarget.454
|
| 172-182 |
|
| Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor |
|
https://doi.org/10.18632/oncotarget.449
|
| 183-194 |
Research Perspectives
|
| MiR181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia |
|
https://doi.org/10.18632/oncotarget.448
|
| 195-202 |
|
| Novel targeted therapies for mantle cell lymphoma |
|
https://doi.org/10.18632/oncotarget.426
|
| 203-211 |
Methodological Reports
|
| A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers |
|
https://doi.org/10.18632/oncotarget.450
|
| 212-223 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC